EWTX Edgewise Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1710072 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY742.1%
TTM EPS YoY633.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE92.1%
ROA85.4%
ROIC (approx.)-16.6%
Asset turnover—
Leverage & solvency
Liabilities / assets8.3%
Debt / equity0.00x
Current ratio12.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.20x
Accruals ratio102.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $31.57M | $47.55M | $42.65M | $43.59M | $37.48M | $33.56M | $36.76M | $36.37M |
| SG&A expense | $14.57M | $14.39M | $11.46M | $12.38M | $9.38M | $9.05M | $9.20M | $9.17M |
| Operating income | -$46.14M | -$61.94M | -$54.12M | -$55.98M | -$46.86M | -$42.61M | -$45.96M | -$45.54M |
| Pretax income | $1.32B | — | — | -$50.22M | -$40.67M | — | — | — |
| Income tax | $155.33M | — | — | — | — | — | — | — |
| Net income | $1.17B | -$57.33M | -$49.01M | -$50.22M | -$40.67M | -$36.12M | -$40.80M | -$39.66M |
| EBITDA | -$45.64M | -$61.44M | -$53.58M | -$55.45M | -$46.36M | -$42.11M | -$45.45M | -$44.96M |
| EPS (basic) | 10.71 | -0.53 | -0.46 | — | -0.39 | -0.34 | -0.43 | — |
| EPS (diluted) | 9.65 | -0.53 | -0.46 | — | -0.39 | -0.34 | -0.43 | — |
| Weighted avg. shares (diluted) | 120.87M | 107.67M | 107.12M | — | 105.49M | 104.94M | 95.13M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $68.68M | $72.32M | $33.21M | $61.15M | $46.00M | $43.40M | $49.92M | $41.67M |
| Current assets | $1.77B | $471.52M | $509.79M | $543.38M | $573.90M | $603.25M | $443.18M | $475.48M |
| PP&E, net | $6.33M | $6.89M | $7.40M | $7.83M | $8.13M | $8.60M | $8.99M | $9.50M |
| Total assets | $1.78B | $479.69M | $518.52M | $552.60M | $583.47M | $613.33M | $454.39M | $486.82M |
| Current liabilities | $144.11M | $29.04M | $22.54M | $27.37M | $21.65M | $20.90M | $21.11M | $23.86M |
| Total liabilities | $147.35M | $31.61M | $25.32M | $30.35M | $24.82M | $24.26M | $24.67M | $27.60M |
| Shareholders' equity | $1.63B | $448.08M | $493.20M | $522.26M | $558.65M | $589.07M | $429.72M | $459.22M |
| Shares outstanding | 109.46M | 107.78M | 107.48M | 106.25M | 105.76M | 105.34M | 95.21M | 94.84M |
| Cash flow statement | ||||||||
| Operating cash flow | -$78.29M | -$42.47M | -$42.54M | -$38.59M | -$34.78M | -$32.58M | -$37.87M | -$26.96M |
| Capital expenditure | $17,000 | $32,000 | $260,000 | $73,000 | $89,000 | $50,000 | $44,000 | $274,000 |
| Free cash flow | -$78.31M | -$42.50M | -$42.80M | -$38.66M | -$34.87M | -$32.63M | -$37.91M | -$27.23M |
| Investing cash flow | $59.67M | $78.49M | $2.43M | $49.76M | $35.72M | -$162.17M | $43.90M | $20.92M |
| Financing cash flow | $14.98M | $3.09M | $12.17M | $3.98M | $1.66M | $188.23M | $2.22M | $2.90M |
| Depreciation & amortization | $500,000 | $500,000 | $537,000 | $525,000 | $500,000 | $500,000 | $513,000 | $577,000 |
| Stock-based compensation | $8.56M | $9.36M | $8.71M | $9.88M | $8.09M | $7.73M | $9.06M | $7.74M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.